Pharma Surge
Pharma Surge
Intelligence Layer
🇺🇸·Jun 16Regulatory

Disruptions in Availability of Breast Biopsy Needles - Letter to Health Care Providers

The FDA issued a LHCP to notify providers that Stereotactic Breast Biopsy Needles (product code KNW)...

Publisher

F
FDA MedWatch

USA

This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.

Read original

At a glance

Publisher
FDA MedWatch
Region
USA
Scope
Regulatory
Published
June 16, 2026
Language
EN

In-platform summary, original article off-platform

This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.

Summary excerpt

The FDA issued a LHCP to notify providers that Stereotactic Breast Biopsy Needles (product code KNW)...

Source route

Continue on fda.gov

Leave the platform to read the original full article on the publisher site.

Source: FDA MedWatch

Scope: Regulatory

Open original article
Disruptions in Availability of Breast Biopsy Needles - Letter to Health Care Providers | Pharma Surge